- Home
- XPEL vs TNGX Comparison
XPEL vs TNGX Comparison
Compare XPEL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEL | TNGX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XPEL | TNGX |
|---|---|---|
| Price | $50.55 | $9.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 298.0K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $461,460,000.00 | $66,501,000.00 |
| Revenue This Year | $16.20 | $53.01 |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $29.88 | ★ N/A |
| Revenue Growth | 10.29 | ★ 53.29 |
| 52 Week Low | $24.25 | $1.03 |
| 52 Week High | $51.64 | $11.20 |
Technical Indicators
Market Signals| Indicator | XPEL | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 80.30 | 52.39 |
| Support Level | $48.54 | $8.89 |
| Resistance Level | $50.00 | $10.22 |
| Average True Range (ATR) | 1.47 | 0.63 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 85.24 | 20.91 |
Price Performance
Historical ComparisonAbout XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.